Unit 8: Therapeutic Duplication

What is therapeutic duplication?

Concurrent use of two or more medications with the same pharmacologic effect or therapeutic class without clinical justification.

What is the key feature of therapeutic duplication?

Unnecessary repetition of therapy.

Is therapeutic duplication usually intentional or unintentional?

Unintentional.

What is a rare intentional reason for therapeutic duplication?

Stepwise titration or synergistic combination therapy.

Therapeutic duplication vs polypharmacy — difference?

Polypharmacy = multiple drugs for different conditions; duplication = same effect/class unnecessarily.

Therapeutic duplication vs drug-drug interaction — difference?

Duplication = same therapy repeated; interaction = drugs affect each other’s action.

Why is understanding duplication important for PTCB?

Technicians must identify and flag duplicate therapy.

Primary healthcare system cause of duplication?

Multiple prescribers without communication.

Care transition risk factor for duplication?

Incomplete medication histories.

EHR-related cause of duplication?

Alert fatigue or system limitations.

Patient behavior cause of duplication?

OTC or supplements with similar ingredients.

Clinician knowledge cause of duplication?

Misunderstanding drug classes.

Pharmacy workflow cause of duplication?

Failure to review full patient profile.

Cardiovascular drug examples prone to duplication?

ACE inhibitors, beta-blockers, diuretics.

Analgesic classes prone to duplication?

NSAIDs and opioids.

Psychiatric drug classes prone to duplication?

SSRIs and benzodiazepines.

Common OTC classes prone to duplication?

Antihistamines and proton pump inhibitors.

Why cardiovascular drugs are high risk?

Serious electrolyte and renal effects.

Why NSAID duplication is dangerous?

GI bleeding and kidney injury risk.

Primary clinical consequence of duplication?

Toxic dosing or amplified effects.

ACE inhibitor duplication risk?

Hyperkalemia and renal impairment.

NSAID duplication risk?

GI bleeding and kidney injury.

Psychiatric duplication risk?

Sedation and cognitive impairment.

Adherence impact of duplication?

Reduced adherence and confusion.

Medication error risk from duplication?

Increased.

Economic impact of duplication?

Higher healthcare costs.

Severe outcomes of duplication?

Hospitalization or long-term morbidity.

Primary pharmacy process to detect duplication?

Medication reconciliation.

When is reconciliation most critical?

Care transitions.

Pharmacy system method to detect duplication?

Electronic patient profile review.

Patient interview importance?

Reveals OTC and supplements.

Who must be contacted when duplication found?

Prescriber.

Why documentation of duplication matters?

Quality assurance and compliance.

Most important prevention step?

Accurate medication history.

Electronic system prevention method?

Duplicate therapy alerts.

Team coordination needed between?

Technicians, pharmacists, prescribers.

Patient education role in prevention?

Clarifies medication purpose and risks.

High-alert focus classes for prevention?

Cardiovascular, analgesics, psychiatric, OTC.

Why alerts should not be overridden automatically?

May miss duplication.

Technician role in duplication detection?

Review patient profile.

Technician role during prescription processing?

Verify duplicate therapy.

Technician action when duplication suspected?

Flag for pharmacist review.

Technician role in refill verification?

Monitor for overlaps.

Technician role in patient education?

Reinforce medication understanding.

Technician documentation role?

Record interventions.

Overall technician impact on duplication?

Prevents medication errors.

First step intervention?

Contact prescriber.

Possible therapy adjustment?

Discontinue one medication.

Alternative intervention?

Dose modification.

Combination therapy intervention?

Switch to single combination drug.

Patient counseling focus?

Risks and safe use.

Documentation purpose after intervention?

Accountability and monitoring.

ISMP focus regarding duplication?

High-risk medications.

Joint Commission requirement related to duplication?

Medication reconciliation.

Why duplication management aligns with regulations?

Patient safety and error prevention.

Duplication prevention contributes to what healthcare goal?

Quality assurance.

Highest-risk population for duplication?

Elderly patients.

Why elderly at higher risk?

Polypharmacy and multiple prescribers.

Age-related factor increasing duplication harm?

Pharmacokinetic/dynamic changes.

Chronic disease patients risk reason?

Complex regimens.

Example chronic duplication scenario?

Two antihypertensives from different providers.

Mental health duplication risk effect?

Excess sedation/cognitive impairment.

Multiple pharmacy users risk?

Incomplete medication profiles.

Mail-order duplication risk cause?

Fragmented records.

Cognitive impairment duplication risk?

Forgotten medications or dosing.

Low health literacy duplication risk?

Misunderstanding instructions.

Tool to reduce duplication in elderly?

Medication reconciliation.

Tool for cognitive impairment patients?

Pill organizers.

Education method for low literacy patients?

Simplified instructions.

Visual aid for duplication prevention?

Color-coded labeling.

Caregiver involvement purpose?

Medication coordination.

Therapeutic duplication is what type of risk?

Preventable medication risk.

Occurs when what happens?

Same therapeutic effect medications used unnecessarily.

Major risk classes?

Cardiovascular, analgesic, psychiatric, OTC.

Consequences range from?

Mild side effects to toxicity/hospitalization.

Who plays major role in prevention?

Pharmacy technicians and pharmacists.

Core prevention tools?

Medication histories, alerts, communication, education.

Overall goal of duplication management?

Safe and effective pharmacotherapy.

Two ACE inhibitors prescribed — what issue?

Therapeutic duplication.

Ibuprofen + naproxen together — issue?

NSAID duplication.

Sertraline + fluoxetine together — issue?

SSRI duplication.

Two antihistamines OTC + Rx — issue?

Therapeutic duplication.

Two beta-blockers — risk?

Bradycardia/hypotension.

Two benzodiazepines — risk?

Excess sedation.

A patient is prescribed lisinopril but already takes enalapril from another provider. What should the pharmacy technician do?
A. Fill both because prescribers differ
B. Flag the profile and notify the pharmacist
C. Tell the patient to stop one
D. Override the alert

B
Explanation: Two ACE inhibitors = therapeutic duplication; technician escalates to pharmacist.

A patient has prescriptions for metoprolol and atenolol from different clinics. What medication issue exists?
A. Drug interaction
B. Polypharmacy
C. Therapeutic duplication
D. Contraindication

C
Explanation: Both are beta-blockers (same class).

A patient takes ibuprofen daily and receives naproxen. What is the primary risk?
A. Hyperkalemia
B. GI bleeding
C. Hypoglycemia
D. Bradycardia

B
Explanation: NSAID duplication → GI bleed/kidney injury.

A patient receives sertraline and fluoxetine from two prescribers. This represents:
A. SSRI therapeutic duplication
B. Drug-drug interaction
C. Polypharmacy
D. Appropriate combination

A
Explanation: Same antidepressant class.

A patient uses diphenhydramine nightly and buys OTC doxylamine. What duplication class?
A. Antihistamines
B. PPIs
C. Benzodiazepines
D. Opioids

A
Explanation: Both sedating antihistamines.

A technician notices duplicate therapy alert in the system. What is the BEST action?
A. Override automatically
B. Ignore if doses differ
C. Notify pharmacist
D. Delete older drug

C
Explanation: Alerts must be evaluated by pharmacist.

Which situation BEST explains the cause of therapeutic duplication?
A. Single prescriber adjusting dose
B. Multiple prescribers without communication
C. Patient adherence issues
D. Drug interaction

B
Explanation: Most common cause.

A patient uses two pharmacies and has overlapping antihypertensives. What risk factor is present?
A. Polypharmacy
B. Fragmented medication records
C. Renal disease
D. Allergy

B
Explanation: Multiple pharmacies → incomplete profiles.

An elderly patient takes two benzodiazepines from different doctors. Why is risk higher?
A. Faster metabolism
B. Increased pharmacodynamic sensitivity
C. Reduced absorption
D. Drug tolerance

B
Explanation: Elderly more sensitive → sedation/falls.

A patient receives two ACE inhibitors. What adverse effect is most likely?
A. Hypoglycemia
B. Hyperkalemia
C. Hyponatremia
D. Tachycardia

B
Explanation: ACE duplication → potassium retention.

Which example represents OTC therapeutic duplication?
A. Omeprazole + esomeprazole
B. Acetaminophen + ibuprofen
C. Lisinopril + amlodipine
D. Metformin + insulin

A
Explanation: Two PPIs.

What pharmacy process is MOST important to detect duplication?
A. Prior authorization
B. Medication reconciliation
C. Inventory review
D. Compounding log

B
Explanation: Core detection method.

A technician discovers duplicate therapy during refill processing. What is their role?
A. Change prescription
B. Counsel patient independently
C. Alert pharmacist
D. Cancel medication

C
Explanation: Technician flags only.

A patient takes two SSRIs and reports sedation. What is this outcome?
A. Drug allergy
B. Therapeutic duplication toxicity
C. Withdrawal
D. Contraindication

B
Explanation: Additive effects.

Which patient is at HIGHEST risk of therapeutic duplication?
A. Young adult, one prescriber
B. Elderly, multiple specialists
C. Child, acute illness
D. Healthy adult OTC use

B
Explanation: Polypharmacy + multiple prescribers.

A prescriber intentionally overlaps two antihypertensives briefly during titration. This is:
A. Unintentional duplication
B. Therapeutic duplication error
C. Intentional therapeutic duplication
D. Contraindication

C
Explanation: Rare justified overlap.